Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients
PDF | HTML | How to cite
Metrics: PDF 1587 views | HTML 2110 views | ?
Michael Constantin Kirchberger1, Alvaro Moreira1, Michael Erdmann1, Gerold Schuler1 and Lucie Heinzerling1
1Department of Dermatology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Ulmenweg 18, 91054 Erlangen, Germany
Lucie Heinzerling, email: [email protected]
Keywords: ipilimumab; pembrolizumab; nivolumab; low-dose; melanoma
Received: February 04, 2018 Accepted: May 30, 2018 Published: June 22, 2018
Dual immune-checkpoint blockade with the anti-PD-1 antibody nivolumab (1 mg/kg) and standard-dose ipilimumab (3 mg/kg) is the mainstay of immunotherapy in advanced melanoma and it is approved since 2016. However, severe side effects (grade 3/4) occur in up to 60% of the patients. Recently, clinical trials have shown similar anti-tumor activity with a more favorable toxicity profile in patients treated with low-dose ipilimumab (1 mg/kg) and standard-dose pembrolizumab (2 mg/kg). In this study we report on the real-world experience of this dosing regime in advanced melanoma patients not eligible for clinical trials. A total of 33 patients with metastatic melanoma (24 with cutaneous and 9 with uveal melanoma) were assessed, retrospectively. Brain metastases were present in 33% of the patients and lactate dehydrogenase was elevated in 70%. Overall response rates were 38% and 0% in cutaneous melanoma and uveal melanoma respectively. Median overall survival was not reached in cutaneous melanoma and was 18 months in uveal melanoma. In 18% of the patients at least one treatment-related severe adverse event was observed. Our observation that the combination of standard dose pembrolizumab and low-dose ipilimumab has a favorable toxicity profile yet anti-tumor activity comparable to the approved standard-dose combination regime in advanced patients not suitable for enrollment in clinical trials is encouraging.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.